OPHT News Alert Ophthotech Corp (OPHT) 44.93 12/25/2014 12:2

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Ophthotech Corp (OPHT) 44.93 $OPHT

Aveo up on (old) news of Klarman stake
Seeking Alpha - at Seeking Alpha - Thu Dec 18, 11:00AM CST

OPHT: 44.93 (+1.06), AVEO: 0.82 (+0.01)

Nasdaq makes annual changes to Biotechnology Index
Seeking Alpha - at Seeking Alpha - Mon Dec 15, 11:36AM CST

TTPH: 38.86 (+0.53), ZSPH: 43.93 (+1.77), AMRN: 0.99 (unch), OPHT: 44.93 (+1.06), AERI: 29.49 (+1.23), ASPX: 49.93 (-0.10), CNCE: 11.76 (+0.11), ICEL: 5.74 (-0.18), GWPH: 68.08 (+1.82), AUXL: 34.40 (+0.18), RTRX: 12.92 (+0.19), RCPT: 122.05 (+4.05), AAVL: 47.30 (-1.20), AKBA: 11.23 (-0.31), EXPR: 14.96 (+0.32), RARE: 45.17 (-0.56), RLYP: 30.35 (-0.22), PETX: 17.05 (+0.42), ENTA: 49.04 (+0.06), RDUS: 37.17 (+0.11), CARA: 9.78 (+0.02), FLML: 17.01 (-0.98), ALIM: 5.43 (-0.06), ANIP: 55.24 (+1.79), ICPT: 151.49 (+5.85), RVNC: 16.65 (+0.42), POZN: 7.86 (+0.07), FPRX: 26.12 (+0.07), ZFGN: 30.99 (+0.67), CRIS: 1.29 (+0.04), QLTI: 3.72 (+0.08), PCYC: 121.84 (+1.15), PTX: 9.05 (+0.28), CLDN: 18.54 (+0.85), RIGL: 2.22 (+0.02), HPTX: 21.91 (-0.08), AMPH: 11.74 (-0.09), INO: 9.11 (-0.09), VSAR: 22.25 (-0.11), FMI: 23.99 (-0.10), TBPH: 14.84 (+0.20), XLRN: 38.80 (+0.80), MGNX: 33.00 (+0.34), INSM: 15.29 (+0.15), ONTX: 3.82 (+0.06), ALDR: 25.67 (+0.43), SAGE: 38.13 (-0.75), KITE: 51.96 (+0.45), CGEN: 8.58 (-0.17), FOLD: 7.94 (+0.06), KPTI: 37.78 (+1.28)

Ophthotech Added to NASDAQ Biotechnology Index
Business Wire - Mon Dec 15, 8:20AM CST
Ophthotech Corporation (NASDAQ: OPHT) today announced that it has been selected for addition to the NASDAQ Biotechnology Index (NASDAQ: NBI). The addition to the NASDAQ Biotechnology Index will become effective upon market open on December 22, 2014.
OPHT: 44.93 (+1.06)

Annual Changes to the NASDAQ Biotechnology Index
GlobeNewswire - Mon Dec 15, 6:10AM CST
The NASDAQ OMX Group, Inc. (Nasdaq:NDAQ) today announced the results of the annual re-ranking of the NASDAQ Biotechnology Index (Nasdaq:NBI), which will become effective prior to market open on Monday, December 22, 2014.
TTPH: 38.86 (+0.53), ZSPH: 43.93 (+1.77), AMRN: 0.99 (unch), OPHT: 44.93 (+1.06), AERI: 29.49 (+1.23), ASPX: 49.93 (-0.10), CNCE: 11.76 (+0.11), ICEL: 5.74 (-0.18), GWPH: 68.08 (+1.82), AUXL: 34.40 (+0.18), RTRX: 12.92 (+0.19), RCPT: 122.05 (+4.05), AAVL: 47.30 (-1.20), AKBA: 11.23 (-0.31), EXPR: 14.96 (+0.32), RARE: 45.17 (-0.56), ZGNX: 1.20 (+0.04), RLYP: 30.35 (-0.22), PETX: 17.05 (+0.42), ENTA: 49.04 (+0.06), RDUS: 37.17 (+0.11), CARA: 9.78 (+0.02), FLML: 17.01 (-0.98), ALIM: 5.43 (-0.06), ANIP: 55.24 (+1.79), ICPT: 151.49 (+5.85), RVNC: 16.65 (+0.42), POZN: 7.86 (+0.07), NDAQ: 48.74 (-0.40), FPRX: 26.12 (+0.07), CRIS: 1.29 (+0.04), ZFGN: 30.99 (+0.67), QLTI: 3.72 (+0.08), PCYC: 121.84 (+1.15), PTX: 9.05 (+0.28), CLDN: 18.54 (+0.85), RIGL: 2.22 (+0.02), HPTX: 21.91 (-0.08), AMPH: 11.74 (-0.09), INO: 9.11 (-0.09), VSAR: 22.25 (-0.11), FMI: 23.99 (-0.10), TBPH: 14.84 (+0.20), XLRN: 38.80 (+0.80), MGNX: 33.00 (+0.34), INSM: 15.29 (+0.15), ONTX: 3.82 (+0.06), ALDR: 25.67 (+0.43), SAGE: 38.13 (-0.75), KITE: 51.96 (+0.45), CGEN: 8.58 (-0.17), FOLD: 7.94 (+0.06), KPTI: 37.78 (+1.28)

Ophthotech Corporation to Present at the Oppenheimer 25th Annual Healthcare Conference
Business Wire - Tue Dec 02, 6:30AM CST
Ophthotech Corporation (NASDAQ:OPHT) announced today that David R. Guyer, M.D., Chairman of the Board and Chief Executive Officer, will present an overview of the Company at the Oppenheimer 25th Annual Healthcare Conference in New York City on Wednesday, December 10, 2014 at 2:45 p.m. ET.
OPHT: 44.93 (+1.06)

InsiderInsights.com Daily Round Up 11/17/14: SFM, INTX, GNRC, GSAT
InsiderInsights - at Seeking Alpha - Tue Nov 18, 5:55AM CST

HCOM: 27.34 (+0.27), IPHI: 15.51 (-0.01), JBHT: 84.91 (-0.02), COV: 103.35 (+0.57), OPHT: 44.93 (+1.06), COP: 70.13 (-0.92), SFM: 32.70 (+0.02), GOOG: 528.77 (-1.82), GSAT: 2.97 (+0.03), STAY: 19.60 (-0.31), ZOES: 29.59 (+1.08), INTX: 3.83 (-0.03), GNRC: 47.26 (-0.24), HZNP: 12.38 (+0.13), TRUE: 23.50 (+0.31)

Why Novartis and Regeneron Care About This Tiny Biotech Stock
Todd Campbell, The Motley Fool - Motley Fool - Fri Nov 14, 2:00PM CST
Source: Flickr user Ali T It may seem a bit odd to think that drug giants Novartis and Regeneron are paying attention to the far smaller Ophthotech Corp . After all, big companies like these tend to acquire small companies or...
OPHT: 44.93 (+1.06), REGN: 400.12 (+6.07), NVS: 93.91 (+0.66)

AVEO Gains on Tivozanib Agreement with Ophthotech - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Nov 13, 4:20PM CST
AVEO Pharmaceuticals' (AVEO) shares gained around 10.9% ever since the company announced a deal with Ophthotech (OPHT).
OPHT: 44.93 (+1.06), AVEO: 0.82 (+0.01), AMAG: 43.02 (+0.90)

Ophthotech Corporation to Present at the Stifel 2014 Healthcare Conference
Business Wire - Thu Nov 13, 6:30AM CST
Ophthotech Corporation (NASDAQ:OPHT) announced today that David R. Guyer, M.D., Chief Executive Officer and Chairman of the Board, will present an overview of the Company at the Stifel 2014 Healthcare Conference in New York City on Tuesday, November 18, 2014 at 8:00 a.m. ET.
OPHT: 44.93 (+1.06)

Aveo licenses tivozanib to Ophthotech
Seeking Alpha - at Seeking Alpha - Wed Nov 12, 8:55AM CST

OPHT: 44.93 (+1.06), AVEO: 0.82 (+0.01)

Ophthotech's (OPHT) CEO Dr. David Guyer on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Tue Nov 11, 11:12AM CST

OPHT: 44.93 (+1.06)

Ophthotech beats 3Q profit forecasts
Automated Insights - Tue Nov 11, 6:34AM CST
NEW YORK (AP) _ Ophthotech Corp. (OPHT) on Tuesday reported net income of $10.9 million in its third quarter.
OPHT: 44.93 (+1.06)

Ophthotech EPS of $0.31
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 5:44AM CST

OPHT: 44.93 (+1.06)

AVEO Enters into Research and Exclusive Option Agreement with Ophthotech for Tivozanib (VEGF inhibitor) for the Treatment of Ocular Diseases
Business Wire - Tue Nov 11, 5:42AM CST
AVEO Oncology (NASDAQ:AVEO) today announced that it has entered into a research and exclusive option agreement with Ophthotech Corporation, under which it has provided Ophthotech an exclusive license to investigate the potential of AVEO's small molecule vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor, tivozanib, outside of Asia for the potential treatment of non-oncologic diseases of the eye.
AVEO: 0.82 (+0.01), OPHT: 44.93 (+1.06)

Ophthotech Provides Business Update and Reports Third Quarter 2014 Financial Results
Business Wire - Tue Nov 11, 5:30AM CST
--- Ophthotech Achieves Enrollment Milestone Triggering Third and Final Tranche in Royalty Financing with Novo A/S -
OPHT: 44.93 (+1.06)

Ophthotech Corporation to Present at the Credit Suisse 2014 Healthcare Conference
Business Wire - Tue Nov 04, 6:30AM CST
Ophthotech Corporation (NASDAQ:OPHT) announced today that David R. Guyer, M.D., Chief Executive Officer and Chairman of the Board, will present an overview of the Company at the 2014 Credit Suisse Annual Healthcare Conference in Phoenix, Arizona on Wednesday, November 12, 2014 at 8:00am MST.
OPHT: 44.93 (+1.06)

Ophthotech Corporation to Announce Third Quarter 2014 Financial Results and Host Conference Call on Tuesday, November 11, 2014
Business Wire - Mon Nov 03, 6:30AM CST
Ophthotech Corporation (Nasdaq:OPHT) today announced that it will release its financial results for the third quarter ended September 30, 2014, on Tuesday, November 11, 2014. Following the announcement, Ophthotech's management will host a live conference call and webcast at 8:00 a.m. Eastern Time to discuss Ophthotech's financial results for the third quarter and provide a general business update.
OPHT: 44.93 (+1.06)

3 Small-Cap Biotech Stocks to Buy if the Market Crashes
Todd Campbell, The Motley Fool - Motley Fool - Wed Oct 15, 1:38PM CDT
The Russell 2000  small-cap stock index is the most widely used proxy for small-cap stocks and the exchange traded fund that tracks that index  has tumbled 11.6% this year. That's a frightening drop, but it's been proven time and time again that...
JNJ: 104.59 (+0.31), INSY: 41.52 (+0.51), PTLA: 28.35 (+0.21), PFE: 31.42 (-0.03), MRK: 57.46 (+0.25), OPHT: 44.93 (+1.06), IWM: 119.76 (-0.10), BMY: 59.15 (-0.01), REGN: 400.12 (+6.07)

Ophthotech Corporation Names Todd N. Smith as Chief Commercial Officer
Business Wire - Fri Oct 03, 6:30AM CDT
--- Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) -
OPHT: 44.93 (+1.06)

Ophthotech Corporation Names Michael G. Atieh as Executive Vice President and Chief Financial and Business Officer
Business Wire - Tue Sep 23, 6:30AM CDT
Ophthotech Corporation (Nasdaq:OPHT) today announced that Michael G. Atieh has been named Executive Vice President, Chief Financial and Business Officer and Treasurer effective September 30, 2014. Mr. Atieh replaces Bruce A. Peacock, Chief Financial and Business Officer and Treasurer, who has notified the Company of his intention to retire effective September 30, 2014.
ACE: 116.03 (-0.18), MRK: 57.46 (+0.25), OPHT: 44.93 (+1.06), TBPH: 14.84 (+0.20)




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Travel Disruptions Reveal the Value of Human Support

Updated Category News Views 95

Air travel’s ugly little secret surfaced again during the recent ground stop: a reservation is easy, but rescuing a trip is labor-intensive, fast-moving work. Internova Travel Group says its people across Travel Leaders Network, Global Travel Collection and ALTOUR moved quickly as cancellations piled up and travelers were left staring at busted itineraries. That is not...

Continue Reading
Label-Free Detection Has a Solid, Narrow Growth Lane

Updated Category News Views 133

Biologics labs are turning into a far better hunting ground for analytical equipment than the old, broad-brush research story suggests. Label-free detection is not a giant market, and nobody should dress it up as one. But the projected move from $0.58 billion in 2026 to $0.85 billion by 2031 points to a useful 8.1% annual growth lane, driven by work researchers genuinely...

Continue Reading
CVRx Lawsuit Puts Barostim Sales Claims Under Hard Scrutiny

Updated Category News Views 91

August 7 turned a compliance disclosure into a wrecking ball for CVRx shareholders. After the company revealed a Department of Justice civil investigative demand and cut its outlook, the stock dropped $3.55, or 60%, to close at $2.39. That is not a routine bad quarter getting punished. It is the market abruptly questioning whether the sales engine, the revenue it...

Continue Reading
ACP's 1-for-4 Split Raises Price, Not Investor Value Yet

Updated Category News Views 68

Four ACP shares are about to become one, and the calculator crowd is liable to make a mountain out of a bookkeeping move. abrdn Income Credit Strategies Fund will execute a 1-for-4 reverse split before the opening bell on December 7, 2026. The quoted share price should rise by roughly four times, but the economic stake held by an investor does not magically get bigger...

Continue Reading
Epic Blue Puts $50,000 of Marketing Work to Use Locally

Updated Category News Views 61

A $50,000 pile of donated know-how can look soft on a spreadsheet, until you remember how often a small nonprofit or early-stage outfit gets ignored because it cannot afford someone to sharpen its message. Epic Blue Marketing, a women-owned firm based in Jackson, Michigan, says it provided that amount in donated and reduced-rate marketing, communications and public...

Continue Reading
Chicago Kertész Show Puts Photography's Quiet Giant First

Updated Category News Views 112

A fork, a plate, and a sharp eye can outlast plenty of louder art. Leica Gallery Chicago is putting that proposition on the wall with André Kertész: The Master, opening December 4, 2026 and running through January 17, 2027. More than thirty signature works is not a sprawling museum survey, and frankly that may be the point. Kertész did not need grand scale to make his...

Continue Reading
Sprocket’s GigaOm Leap Puts PTaaS Claims Under Scrutiny

Updated Category News Views 44

Security vendors love a shiny quadrant, but this one deserves more than the usual polite golf clap. Sprocket Security moved from Challenger and Outperformer in GigaOm’s 2025 Penetration Testing as a Service assessment to a Leader in the version 5 report released in 2026. That is a meaningful jump in a category where buyers are tired of annual testing reports that go...

Continue Reading
Rock Gate Buys Aviation Niche Player Blast Deflectors

Updated Category News Views 110

Jet exhaust is not glamorous, but somebody has to keep it from battering everything nearby. Rock Gate Partners’ acquisition of Blast Deflectors, Inc. puts money behind one of those stubbornly unsexy industrial niches where engineering credibility matters far more than a flashy sales pitch. The transaction closed October 16, 2026, and Northborne Partners announced...

Continue Reading
Rosalind Franklin University’s $23.8M Scholarship Win

Updated Category News Views 80

Twenty-three million dollars can disappear fast in graduate health education, which is exactly why Rosalind Franklin University’s campaign result deserves more than a polite round of applause. The university’s five-year Empowering Scholars effort closed in June 2026 with $23,836,272 raised, clearing its $20 million target by roughly 19%. In a world where institutions...

Continue Reading
Tessera Delisting Leaves HLSQ in a Tougher Market Ahead

Updated Category News Views 116

November delivered a nasty little truth serum for Tessera Defense and Homeland Security: exchange status is not a cosmetic detail when the stock’s selling price has collapsed. On November 10, NYSE Regulation suspended trading in the company’s common shares on NYSE American and began delisting proceedings. By November 17, Tessera had a chance to request review by the...

Continue Reading

Top 5 Most Recently Viewed Articles

Epic Yoga Event by Real Essentials to Support Ovarian Cancer

Updated Category News Views 70

Real Essentials Teams Up for Ovarian Cancer Awareness To honor Ovarian Cancer Awareness Month, Real Essentials, a brand celebrated for its affordable yet high-quality apparel, partnered with Not These Ovaries, a nonprofit organization dedicated to ovarian cancer. Together, they created a unique yoga event that aimed to raise both awareness and funds for essential ovarian...

Continue Reading
MKDWELL Tech Inc. Posts H1 2024 Financial Results Drop

Updated Category News Views 115

MKDWELL Tech Inc. Financial Overview for 2024 MKDWELL Tech Inc. (NASDAQ: MKDW), a key player in the automotive electronics industry with operations in Mainland China and Taiwan, has provided an update on its financial status for the first half of the fiscal year. The latest results show a significant decline in revenue compared to the same period in the previous year....

Continue Reading
Northwest Pipe Company Strengthens Production with New Facility

Updated Category News Views 212

Northwest Pipe Company Enhances Production Capacity Northwest Pipe Company, renowned for its expertise in water-related infrastructure, has announced a significant upgrade to its production facilities. The company has recently inaugurated a new precast concrete pipe and manhole manufacturing plant aimed at addressing the rising demand in the region. With this strategic...

Continue Reading
Allient Inc. Posts Third Quarter Gains Driven by Initiatives

Updated Category News Views 99

Allient Inc. Announces Impressive Third Quarter Results Allient Inc. (NASDAQ: ALNT), a global leader in precision and specialty Motion, Controls and Power products, has announced significant financial results for its third quarter. Despite facing challenges in key industrial and vehicle markets, the company has demonstrated resilience through its operational improvements...

Continue Reading
Fulcrum Therapeutics Investor Event to Unveil PIONEER Findings

Updated Category News Views 191

Introduction to Fulcrum Therapeutics Fulcrum Therapeutics, Inc. (NASDAQ: FULC), a pioneering biopharmaceutical company, is dedicated to enhancing the lives of individuals grappling with genetically defined rare diseases. Their primary focus is on developing innovative small molecules that target specific diseases at their root cause. This commitment drives their latest...

Continue Reading